{"transactions":[{"id":686878,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T21:00:03.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":false,"shares":272056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vested on August 14, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vested on August 14, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":272056},"source":{"system":"sec-edgar","filing":"0001683168-26-006493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826006493/ownership.xml","form_type":"4"}},{"id":686877,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2026-08-14T21:00:03.000Z","date":"2026-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":120521,"price":1.01,"value":121726.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 120,521 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of Issuer's common stock on August 14, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents 120,521 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units (\"RSUs\")."}],"balance_after":301716,"source":{"system":"sec-edgar","filing":"0001683168-26-006493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826006493/ownership.xml","form_type":"4"}},{"id":686876,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2026-08-14T21:00:03.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":true,"shares":272056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the issuance of 272,056 shares of common stock from the vesting and settlement of 272,056 RSUs, which number excludes the withholding of 120,521 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the issuance of 272,056 shares of common stock from the vesting and settlement of 272,056 RSUs, which number excludes the withholding of 120,521 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1)."}],"balance_after":422237,"source":{"system":"sec-edgar","filing":"0001683168-26-006493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826006493/ownership.xml","form_type":"4"}},{"id":765945,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44727,"kind":"person","name":"Zabrowski Dan","position":1,"cik":"0001940818","reported_name":"Zabrowski Dan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:15:21.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004260/ownership.xml","form_type":"4"}},{"id":765944,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:14:24.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC (\"KVI\"), and serves on the board of directors (the \"Board\") of Actuate Therapeutics, Inc. (\"Actuate\"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the \"Kairos Funds\") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC (\"KVI\"), and serves on the board of directors (the \"Board\") of Actuate Therapeutics, Inc. (\"Actuate\"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the \"Kairos Funds\") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004257/ownership.xml","form_type":"4"}},{"id":766188,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":30337,"kind":"person","name":"Sawhney Roger","position":1,"cik":"0001858748","reported_name":"Sawhney Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:10:59.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004255","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1858748/000168316826004255/ownership.xml","form_type":"4"}},{"id":765943,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44726,"kind":"person","name":"RONNEBERG AMY L","position":1,"cik":"0001380292","reported_name":"RONNEBERG AMY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:09:49.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004251/ownership.xml","form_type":"4"}},{"id":765942,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":25050,"kind":"person","name":"Keyes Jason A","position":1,"cik":"0001678152","reported_name":"Keyes Jason A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:04:58.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004245/ownership.xml","form_type":"4"}},{"id":765941,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:03:42.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004243/ownership.xml","form_type":"4"}},{"id":765937,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:02:24.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004241/ownership.xml","form_type":"4"}},{"id":822843,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-01T21:19:52.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":237000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":237000,"derivative":{"exercise_price":2.49,"expiration_date":"2036-04-01","underlying":"Common Stock","underlying_shares":237000},"source":{"system":"sec-edgar","filing":"0001683168-26-002582","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826002582/ownership.xml","form_type":"4"}},{"id":822842,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-01T21:19:31.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":105000,"derivative":{"exercise_price":2.49,"expiration_date":"2036-04-01","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001683168-26-002581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826002581/ownership.xml","form_type":"4"}},{"id":822841,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-01T21:19:11.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":105000,"derivative":{"exercise_price":2.49,"expiration_date":"2036-04-01","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001683168-26-002580","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826002580/ownership.xml","form_type":"4"}},{"id":905194,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T23:10:04.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":272055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vest on August 14, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vest on August 14, 2026."}],"balance_after":272056,"derivative":{"underlying":"Common Stock","underlying_shares":272055},"source":{"system":"sec-edgar","filing":"0001683168-26-001039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826001039/ownership.xml","form_type":"4"}},{"id":905193,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2026-02-13T23:10:04.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":121874,"price":4.33,"value":527714.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 121,874 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of Issuer's common stock on February 13, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents 121,874 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units (\"RSUs\")."}],"balance_after":150181,"source":{"system":"sec-edgar","filing":"0001683168-26-001039","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826001039/ownership.xml","form_type":"4"}},{"id":905192,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2026-02-13T23:10:04.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":272055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the issuance of 272,055 shares of common stock from the vesting and settlement of 272,055 RSUs, which number excludes the withholding of 121,874 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the issuance of 272,055 shares of common stock from the vesting and settlement of 272,055 RSUs, which number excludes the withholding of 121,874 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1)."}],"balance_after":272055,"source":{"system":"sec-edgar","filing":"0001683168-26-001039","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826001039/ownership.xml","form_type":"4"}},{"id":944474,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"ten_percent_owner":true}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":2,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-01-07T17:45:49.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":280000,"price":5.8,"value":1624000.0,"ownership":{"direct":false,"nature":"By Kairos Venture Partners II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":904795,"source":{"system":"sec-edgar","filing":"0001011438-26-000005","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000101143826000005/form4.xml","form_type":"4"}},{"id":1099434,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77989,"kind":"person","name":"Bios 2024 Co-Invest, LP","position":3,"cik":"0002028708","reported_name":"Bios 2024 Co-Invest, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-06-30T13:03:52.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":71428,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":71428},"source":{"system":"sec-edgar","filing":"0001104659-25-063993","document":"tm2519406-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/2028708/000110465925063993/tm2519406-1_4seq1.xml","form_type":"4"}},{"id":1099433,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77989,"kind":"person","name":"Bios 2024 Co-Invest, LP","position":3,"cik":"0002028708","reported_name":"Bios 2024 Co-Invest, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T13:03:52.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":7,"value":499996.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Securities Purchase Agreement\"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the \"Common Stock\"), and warrants to purchase 71,428 shares of Common Stock (the \"Warrants\"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":196428,"source":{"system":"sec-edgar","filing":"0001104659-25-063993","document":"tm2519406-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028708/000110465925063993/tm2519406-1_4seq1.xml","form_type":"4"}},{"id":1099351,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-06-30T13:02:42.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Footnote 3 Continue) Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Footnote 3 Continue)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":71428,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":71428},"source":{"system":"sec-edgar","filing":"0001104659-25-063992","document":"tm2519406-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925063992/tm2519406-3_4seq1.xml","form_type":"4"}},{"id":1099350,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T13:02:42.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":7,"value":499996.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Securities Purchase Agreement\"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the \"Common Stock\"), and warrants to purchase 71,428 shares of Common Stock (the \"Warrants\"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Footnote 3 Continue) Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Footnote 3 Continue)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":196428,"source":{"system":"sec-edgar","filing":"0001104659-25-063992","document":"tm2519406-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925063992/tm2519406-3_4seq1.xml","form_type":"4"}},{"id":1099667,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-06-30T13:01:13.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":71428,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":71428},"source":{"system":"sec-edgar","filing":"0001104659-25-063991","document":"tm2519406-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925063991/tm2519406-2_4seq1.xml","form_type":"4"}},{"id":1099666,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T13:01:13.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":7,"value":499996.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Securities Purchase Agreement\"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the \"Common Stock\"), and warrants to purchase 71,428 shares of Common Stock (the \"Warrants\"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":196428,"source":{"system":"sec-edgar","filing":"0001104659-25-063991","document":"tm2519406-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925063991/tm2519406-2_4seq1.xml","form_type":"4"}},{"id":1135290,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2025-05-23T20:37:19.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC (\"KVI\"), and serves on the board of directors (the \"Board\") of Actuate Therapeutics, Inc. (\"Actuate\"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the \"Kairos Funds\") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC (\"KVI\"), and serves on the board of directors (the \"Board\") of Actuate Therapeutics, Inc. (\"Actuate\"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the \"Kairos Funds\") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4."}],"balance_after":15000,"derivative":{"exercise_price":10.1,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-25-004001","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825004001/ownership.xml","form_type":"4"}},{"id":1135545,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":30337,"kind":"person","name":"Sawhney Roger","position":1,"cik":"0001858748","reported_name":"Sawhney Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-05-23T20:05:33.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":10.1,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-25-003993","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1858748/000168316825003993/ownership.xml","form_type":"4"}},{"id":1135289,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44727,"kind":"person","name":"Zabrowski Dan","position":1,"cik":"0001940818","reported_name":"Zabrowski Dan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-05-23T20:05:31.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":10.1,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-25-003990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825003990/ownership.xml","form_type":"4"}},{"id":1135287,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2025-05-23T20:05:29.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":10.1,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-25-003988","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825003988/ownership.xml","form_type":"4"}},{"id":1135288,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":25050,"kind":"person","name":"Keyes Jason A","position":1,"cik":"0001678152","reported_name":"Keyes Jason A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-05-23T20:05:28.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":10.1,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-25-003992","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825003992/ownership.xml","form_type":"4"}},{"id":1135286,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44726,"kind":"person","name":"RONNEBERG AMY L","position":1,"cik":"0001380292","reported_name":"RONNEBERG AMY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-05-23T20:05:27.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":10.1,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-25-003991","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825003991/ownership.xml","form_type":"4"}},{"id":1183406,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:44:57.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":204285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter."}],"balance_after":204285,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":204285},"source":{"system":"sec-edgar","filing":"0001683168-25-002212","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002212/ownership.xml","form_type":"4"}},{"id":1183405,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:44:57.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":66503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":66503,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":66503},"source":{"system":"sec-edgar","filing":"0001683168-25-002212","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002212/ownership.xml","form_type":"4"}},{"id":1183404,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:43:25.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":110346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter."}],"balance_after":110346,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":110346},"source":{"system":"sec-edgar","filing":"0001683168-25-002210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002210/ownership.xml","form_type":"4"}},{"id":1183403,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":1,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:43:25.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":51046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":51046,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":51046},"source":{"system":"sec-edgar","filing":"0001683168-25-002210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002210/ownership.xml","form_type":"4"}},{"id":1183402,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:41:10.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":41899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter."}],"balance_after":41899,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":41899},"source":{"system":"sec-edgar","filing":"0001683168-25-002208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002208/ownership.xml","form_type":"4"}},{"id":1183401,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:41:10.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":49394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":49394,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":49394},"source":{"system":"sec-edgar","filing":"0001683168-25-002208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002208/ownership.xml","form_type":"4"}},{"id":1427914,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:56.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":8,"value":18592.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-091372","document":"tm2422197-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924091372/tm2422197-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1427913,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:56.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":17361,"price":8,"value":138888.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":980433,"source":{"system":"sec-edgar","filing":"0001104659-24-091372","document":"tm2422197-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924091372/tm2422197-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1427912,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:56.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":5314,"price":8,"value":42512.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001104659-24-091372","document":"tm2422197-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924091372/tm2422197-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1428413,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":8,"value":18592.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-091371","document":"tm2422197-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924091371/tm2422197-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1428412,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":17361,"price":8,"value":138888.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":980433,"source":{"system":"sec-edgar","filing":"0001104659-24-091371","document":"tm2422197-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924091371/tm2422197-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1428411,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":5314,"price":8,"value":42512.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001104659-24-091371","document":"tm2422197-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924091371/tm2422197-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1427778,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:45:30.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":8,"value":18592.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-091370","document":"tm2422197-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924091370/tm2422197-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1427777,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:45:30.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":17361,"price":8,"value":138888.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":980433,"source":{"system":"sec-edgar","filing":"0001104659-24-091370","document":"tm2422197-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924091370/tm2422197-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1427776,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:45:30.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":5314,"price":8,"value":42512.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001104659-24-091370","document":"tm2422197-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924091370/tm2422197-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1431352,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"15,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in full on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431351,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":28464,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":28464},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431350,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":49984,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":49984},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431349,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":24138,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24138},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431348,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":132908,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":132908},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431347,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":230597,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":230597},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431346,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":138889,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":138889},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431345,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":146870,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":146870},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431344,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":69445,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":69445},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431343,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":726163,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":726163},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431342,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":1058318,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1058318},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431341,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":18750,"price":8,"value":150000.0,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1184795,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431340,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":28464,"price":5.27,"value":150005.28,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1203545,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431339,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":49984,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":321781,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431338,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":24138,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":254735,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431337,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":132908,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":271797,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431336,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":230597,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":230597,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431335,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":138889,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":138889,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431334,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":146870,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":873033,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431333,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":69445,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1175081,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431332,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":726163,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":726163,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431331,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":1058318,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1105636,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1433614,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44727,"kind":"person","name":"Zabrowski Dan","position":1,"cik":"0001940818","reported_name":"Zabrowski Dan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-14T23:30:35.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"15,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in full on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-24-089797","document":"tm2421559-8_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924089797/tm2421559-8_4.xml","form_type":"4"}},{"id":1433613,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":23328,"kind":"person","name":"SCHMITT DANIEL M","position":1,"cik":"0001318470","reported_name":"SCHMITT DANIEL M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Restricted Stock Units","published_at":"2024-08-14T23:29:53.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":544111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"544,111 restricted stock units granted upon the closing of the issuer's initial public offering on August 14, 2024, 50% of which vest on the first anniversary of the closing of such transaction and 50% of which vest on the second anniversary of the closing of such transaction."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"544,111 restricted stock units granted upon the closing of the issuer's initial public offering on August 14, 2024, 50% of which vest on the first anniversary of the closing of such transaction and 50% of which vest on the second anniversary of the closing of such transaction."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":544111},"source":{"system":"sec-edgar","filing":"0001104659-24-089795","document":"tm2421559-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924089795/tm2421559-7_4seq1.xml","form_type":"4"}},{"id":1433612,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-14T23:28:37.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":234971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"234,971 stock options granted upon the closing of the issuer's initial public offering on August 14, 2024, 25% of which vest on June 1, 2025 and the remaining 75% of which vest in equal monthly installments during the 36 months following June 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":8,"expiration_date":"2034-08-14","underlying":"Common Stock","underlying_shares":234971},"source":{"system":"sec-edgar","filing":"0001104659-24-089794","document":"tm2421559-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924089794/tm2421559-4_4seq1.xml","form_type":"4"}},{"id":1433611,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":25050,"kind":"person","name":"Keyes Jason A","position":1,"cik":"0001678152","reported_name":"Keyes Jason A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-14T23:27:32.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in three equal installments on the first, second, and third anniversary of the grant date, subject to the reporting person's continued service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-24-089793","document":"tm2421559-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924089793/tm2421559-3_4seq1.xml","form_type":"4"}},{"id":1433610,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44726,"kind":"person","name":"RONNEBERG AMY L","position":1,"cik":"0001380292","reported_name":"RONNEBERG AMY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-14T23:26:27.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in three equal installments on the first, second, and third anniversary of the grant date, subject to the reporting person's continued service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-24-089792","document":"tm2421559-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924089792/tm2421559-5_4seq1.xml","form_type":"4"}},{"id":1433865,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":30337,"kind":"person","name":"Sawhney Roger","position":1,"cik":"0001858748","reported_name":"Sawhney Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-14T23:25:49.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"30,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in three equal installments on the first, second, and third anniversary of the grant date, subject to the reporting person's continued service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-24-089791","document":"tm2421559-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1858748/000110465924089791/tm2421559-6_4seq1.xml","form_type":"4"}},{"id":1433956,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Aaron G.L. Fletcher"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The options vest and become exercisable on August 12, 2025, subject to the Mr. Fletcher's continuing service on the Issuer's Board of Directors through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":56,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433955,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":3528,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":3528},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":55,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433954,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":26355,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":26355},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":54,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433953,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":8068,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":8068},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":53,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433952,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":573394,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":573394},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":52,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433951,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":78267,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78267},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":51,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433950,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":484638,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":484638},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":50,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433949,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":74202,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74202},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":49,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433948,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":2094650,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2094650},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":48,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433947,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":326547,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":326547},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":47,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433946,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":2022029,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2022029},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":46,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433945,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":309589,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":309589},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":45,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433944,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":44559,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44559},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":44,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433943,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":332867,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":332867},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":43,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433942,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":101900,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":101900},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":42,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433941,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":147047,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":147047},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":41,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433940,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":23628,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23628},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":40,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433939,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":176499,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":176499},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":39,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433938,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":54032,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54032},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":38,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433937,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":153702,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":153702},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":37,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433936,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":61857,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":61857},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433935,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":462073,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":462073},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433934,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":141457,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":141457},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433933,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":307538,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":307538},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433932,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":525797,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":525797},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433931,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":884427,"ownership":{"direct":false,"nature":"Directly held by Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":884427},"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433930,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":9,"value":20916.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}},{"id":1433929,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":1,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":2,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":3,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:54:46.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":3528,"price":5.27,"value":18592.56,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":133572,"source":{"system":"sec-edgar","filing":"0001104659-24-089825","document":"tm2421559-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924089825/tm2421559-11_4seq1.xml","form_type":"4"}}],"next_cursor":"2024-08-14T20:54:46.000000Z,1433929"}